Tracking cancer genes after stem cell transplant with digital PCR
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses a precise blood test called digital PCR to measure tiny amounts of leftover cancer cells in patients who have had a stem cell transplant. It helps doctors see how well the transplant is working and if more treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a known cancer-related gene change found at diagnosis that can be tracked in blood tests.
- Your new stem cells must have started making white blood cells (called engraftment).
- You must have had at least one MRD test using digital PCR after your transplant.
- You cannot have had a relapse or died before your first digital PCR test.
- If your only gene changes are in DNMT3A, TET2, or ASXL1, or are inherited from a parent, you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
This study looks at whether a simple blood test that measures tumor DNA (called ctDNA) can track how well treatment is working in children with acute leukemia. The goal is to see if the blood test can give the same information as a bone marrow test, which is more invasive.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.